We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


TriLink Awarded SBIR Phase II Grant: Chemical Determinants of DNA Ligase Fidelity

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "TriLink Awarded SBIR Phase II Grant: Chemical Determinants of DNA Ligase Fidelity"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:

 In these continued studies, the utility of chemically modified components will be explored as a potential means of enhancing ligation fidelity in a variety of advanced applications that employ DNA ligase, including SNP detection, proximity ligation, and sequencing by ligation.  This is the fourth Phase II grant TriLink has been awarded and it will be funded through February 2012.

Dr. Natasha Paul, lead biologist, commented, “This grant demonstrates TriLink’s continued focus on solving molecular biology problems through chemistry.”

TriLink’s CEO, Richard Hogrefe stated, “TriLink is first and foremost a research and development team. We are committed to our science, as well as supporting our customers’ scientific advancements, and are confident we will soon offer a number of novel ligation products to compliment our CleanAmp™ PCR line of products.”